IMPROVED CONTROLLED RELEASE FORMULATION

Abstract: A controlled release formulation which comprises an organic acidic compound or an acid anhydride or ester capable of generating one of the organic acidic compounds through hydrolysis together with an active ingredient and collagen as a carrier, said formulation being capable of exhibiting a predetermined release profile of the active ingredient. A process for producing said formulation is also provided.

Description: The present invention relates to a controlled release formulation. More particularly, it relates to a controlled release formulation for human or veterinary use, which can control the release profile of an active ingredient contained therein. Sustained release formulations, which release an active ingredient over a long period of time, have been recognized to be useful in various aspects: increase of therapeutical effect due to prolonged retention of an active ingredient over effective level in the blood; decrease of side-effects by reducing the maximal blood level of the active ingredient; simplification of administration methods and reduction of patient's pain thanks to decrease of administration frequency. Various polymers are known to serve as a carrier material for preparing sustained release formulations. Examples of polymers employable in sustained release formulations are vinyl polymers, silicones, polyvinylalcohols, polypeptides, chitosan, collagen, polylactic acid and polyglycolic acid. Among them, polypeptides, chitosan, collagen, polylactic acid, and polyglycolic acid are said preferable because they are biodegradable. Above all, collagen, which is a protein constituting one third of total proteins of mammalians, is highly biocompatible and considered a most preferred carrier. The inventors of the present invention recognized such usefulness of collagen, and succeeded in producing sustained release formulations using the same as a carrier matrix; see JP-A-126217/1985, 97918/1985, 84213/1985, 89418/1985, 112713/1985, 236729/1986, and 230729/1987. However, the release of an active ingredient cannot be adjusted in the manner as desired with the sustained release formulations disclosed in the above publications, although they successfully attain sustained release of an active ingredient. Accordingly, an extended study is necessary in order to prepare the above-mentioned formulations in which the release rate or release profile of an active ingredient is suitably controlled. Such controlled release becomes necessary when the disease to be treated, the nature of an active ingredient to be used or the duration of administration of the formulation requires particular release rate or release profile. In view of the above, the inventors of the present invention continued the study looking for an ideal controlled release formulation which permits arbitrary control of the release rate or release profile, and found that an addition of a predetermined amount of an organic acidic compound as an additive to a sustained release formulation comprising collagen and an active ingredient allowed suitable control of a release rate or release profile of the active ingredient. The present invention has been completed on the basis of this finding. Thus, the present application provides a controlled release formulation comprising an active ingredient and collagen as a carrier, which is characterized in that it comprises in the formulation at least one organic acidic compound or an acid anhydride or ester capable of generating one of said acidic compounds through hydrolysis. The present application also provides a process for preparing a controlled release formulation comprising an active ingredient and collagen as a carrier, said formulation exhibiting a predetermined release profile of the active ingredient, which process is characterized in that at least one organic acidic compound or an acid anhydride or ester capable of generating one of the acidic compounds through hydrolysis is incorporated into the formulation during the production process thereof. The present application further provides a method for controlling the release rate or release profile of an active ingredient from a sustained release composition comprising collagen and said active ingredient, characterized in that said composition comprises additionally at least one organic acidic compound or an acid anhydride or ester capable of generating one of the organic acidic compounds through hydrolysis. The term "organic acidic compound" herein employed denotes a pharmaceutically or veterinarily acceptable organic compound, an aqueous solution of which shows below pH 7. Examples of such organic compounds are organic compounds possessing one or more carboxylic groups, such as citric acid, tartaric acid, succinic acid and acetic acid, and amino acids such as aspartic acid, glutamic acid, glycine and alanine, which show below pH 7 when dissolved in water in spite of bearing a basic functional group or groups. Other compounds which are free from carboxylic group but show below pH 7 when dissolved in water, such as ascorbic acid, are included in organic acidic compounds according to the present invention. Citric acid, among them, is most preferred. Acid anhydrides or esters capable of generating the acidic compound through hydrolysis can be employed in lieu of the above-mentioned organic acidic compounds. Examples of the anhydrides or esters are succinic anhydride, glutamic anhydride and isocitric acid lactone. The organic acidic compounds and the acid anhydrides or esters capable of generating one of the acidic compounds will hereinafter collectively be referred to as "acidic compounds" for simplicity purpose. The controlled release formulation of the invention may contain a single acidic compound. However, two or more acidic compounds listed above may be employed in the formulation of the invention. The content of the acidic compound(s) in the formulation varies depending on the nature of the acidic compound(s) to be used and the release rate or release profile to be attained. In general, the amount of the acidic compound(s) to be added ranges from 1 to 50 % by weight in terms of the total weight of the formulation. Specifically, preferable amount of citric acid, alanine and glycine to be added are about 5-50 %, 5-50 %, and 5-45 % by weight respectively. More specifically, addition of about 5-20 % by weight of citric acid or about 5-30 % by weight of glycine is especially preferred where the active ingredient is a growth hormone-releasing factor, about 5-20 % by weight of citric acid or about 10-30 % by weight of glycine is especially preferred where the active ingredient is an interferon, and about 5-20 % by weight of citric acid is especially preferred where the active ingredient is calcitonin. As far as the above active ingredients are concerned, the amount of the active ingredient released during a given period of time can be increased by increasing the amount of an organic acidic compound to be added. Collagen employed in the formulations of the invention as a carrier is a substance which is found widely in animals. It constitutes one third of total proteins of mammalians. According to the recent finding, collagen has many variations. For instance, it is known that there are 10 or more variations of collagen in mammalians and birds, which differ each other from the genetic point of view, and classified into Type I to Type X. Preferred collagen employed according to the present invention is of Type I originated from mammalians, although other collagenes are employable. Collagen is known to be compatible with animal tissue or organ and has widely been used as a surgical suture in medical operations. However, for securing complete safety, there may be employed atelocollagen which has far less antigenicity and which is obtained by removing telopeptide regions from the collagen molecules. There is no limitation to the active ingredient employable in the controlled release formulation of the present invention, and various bioactive substances such as prostagrandins, prostacyclines, vitamins, steroids, proteins and peptides are illustrated as the active ingredient. However, the formulations of the invention are most suitable to those which contain an active ingredient usually employed in an aqueous solution and in a very small amount in clinical use. Most preferred ingredients are bioactive proteins and peptides such as cytokines, hormones, hormone releasing factors, hormone-release inhibiting factors, growth factors and enzymes. Cytokine is a general term for bioactive and soluble substances which are released from macrophages or lymphocytes when they are stimulated by antigens or mitogens. Cytokine produced by lymphocytes is referred to as lymphokine and that produced by macrophages or monocytes is called monokine. There is no limitation to cytokines employable in the formulation of the invention and exemplified by interferon (IFN), interleukin (IL), colony-stimulating factor (CSF), macrophage activating factor (MAF), and macrophage migration inhibiting factor (MIF). The term "interferon" herein used denotes any type of interferons including α-, β-, and γ-interferons, as well as a blend thereof. Likewise, interleukin includes IL-1, IL-2, IL-3, and colony-stimulating factor includes multi-CSF, granulocyte-monocyte macrophage CSF (GM-CSF), granulocyte CSF (G-CSF), monocyte macrophage CSF (M-CSF), and a mixture thereof. Hormones are substances which are produced in, and secreted from, a particular cell in response to biological interior or exterior information, and convey the information to other cell, i.e., target cell for hormone, through body fluid. There is no limitation to the hormones employable in the formulation of the invention and illustrated by growth hormone (GH) and calcitonin (CT). Hormone-releasing factors are substances which cause secretion of hormones by direct action to endocrine glands. Examples of hormone-releasing factors employable in the formulation of the invention are growth hormone-releasing factor(GRF) and luteinizing hormone-releasing factor LH-RH), although the factors are not limited thereto. GRFs are peptides which have an ability of stimulating growth hormone secretion and those consisting of 44, 40, 37 and 29 amino acids are known to be active. Any of these GRFs and a mixture thereof can be employed according to the invention. Hormone-release inhibiting factor, which is a substance inhibiting a release of hormone by direct action to an endocrine organ, is another example of the active ingredient employed in the present invention. Examples of hormone-release inhibiting factors are somatostatin and melanostatin. Growth factors are further examples of the active ingredient preferably employed in the formulation of the invention, which factors are substances defined as having an ability of promoting growth of animal cells both in vitro and in vivo but not belonging to nutrients. Typical growth factors are somatomedin (SM), nerve growth factor (NGF), epidermal growth factor (EGF), fibroblast growth factor (FGF), transforming growth factor (TGF), erythropoietin (EPO) and platelet-derived growth factor (PDGF). Above-mentioned somatomedin (SM) means any member of the somatomedin group, such as SM-A, SM-B, SM-C and further insulin-like growth factor (IGF)-I, (IGF)-II as well as MSA (multiplication stimulating activity). It is reported that SM-C is the same as IGF-I. Anyway, any of these peptides or a mixture of two or more thereof may be used in the present invention. No limitation exists to enzymes employable in the formulation of the invention. Such enzymes are illustrated by thrombus lysing agent, such as tissue plasminogen activator (TPA) and urokinase (UK). The proteins and peptides specifically illustrated above under categories of cytokines, hormones, hormone-releasing factor, hormone-release inhibiting factors, growth factors, and enzymes include substances which cannot definitely and primarily be classified because of variety of actions and origins thereof. The present invention can be applied not only to the substances illustrated or categorized in the above, but also to other peptides, proteins and glycoproteins, such as an enzyme inhibitor (e.g. a collagenase inhibitor, tissue inhibitor of metallopreteinase (TIMP)), bone morphogenetic protein (BMP) and a certain antibody. The above proteins and peptides employed in the formulation of the present invention may come from any origin and may be obtained by extract from relevant tissue or organ, by chemical synthesis, or by recombinant DNA technology. The skilled person in the art will easily understand that the formulation of the present invention can contain one or more of the active ingredients illustrated above. The controlled release formulation of the invention can be produced by one of conventional methods except that the method includes an additional step of incorporating into other starting materials a predetermined amount of one or more of acidic compounds so that the predetermined amount of the acidic compound(s) may control the release rate or release profile of an active ingredient in the manner as desired. For example, the formulation may be prepared by the following steps: Lyophilizing a mixture comprising an active ingredient, collagen and an appropriate amount of acidic compound, pulverizing the resulting solid product, and compression-molding the pulverized product in a template, or charging the above-mentioned mixture in a template and condensing or drying the mixture, to obtain the formulation in a solid form, whereby any formulation having desired size and shape suitable for particular administration route and particular position to be applied can be obtained. Specific examples of the shape of the formulation are bar-like, rod-like, needle-like, disk-like, film-like, and spherical shape. The afore-mentioned mixture can also be blended and kneaded in the presence of an appropriate amount of water or buffer, and subjected to injection-molding followed by drying to prepare a needle-like or bar-like shaped formulation. In the latter method, collagen which exhibits acidic to neutral pH may be employed because collagen has a fiber-forming property under condition of basic to neutral pH. The above methods do not require a binding agent, heat and organic solvents, and therefore, the methods are especially suitable for the preparation of the formulation containing an active ingredient which is unstable under existence of the above factors. The specific embodiments for producing the formulation of the invention are presented above by way of illustration and should not be constructed as limiting thereto in any respect. The sustained release formulation of the invention can be administered to a living body through any one of conventional methods. However, suitable administration route is parenteral administration, and injection, implantation, and insertion or implantation during surgical operation are most preferred. Direct application of the formulation of the invention in a solid form brings excellent therapeutical effect. Topical administration is most suitable with the formulation in the form of a film or a sheet. Thus, the formulation of the invention can be applied systemically or topically. With the controlled release formulation of the invention, the release rate of an active ingredient can be adjusted as desired by virtue of the addition of an organic acidic compound. In addition, the carrier contained in the formulation is collagen which is highly biocompatible and biodegradable. Accordingly, the formulation of the invention is safe to use and especially suitable for the treatment of patients and veterinary. Fig. 1 of the accompanying drawings shows the time-course of the amount of GRF (1-29) released from the formulation of the invention during the release test in vitro (See Experiment 1). Vertical and horizontal axes show the accumulated amount of GRF released from the formulation and the time-course (days) respectively. The amount of GRF is indicated with the percentage (%) of the initial amount contained in the formulation. The symbols ▴, ▪, and  respectively represent the formulations obtained in Example 1, Example 2, and Reference Example 1. Fig. 2 shows the correlation between the accumulated total amount of GRF (1-29) released for three days from three different formulations obtained in Example 1, Example 2 and Reference Example 1 and the amounts of citric acid incorporated into respective formulations. Fig. 3 shows the time-course of the amount of calcitonin remained in the formulations of the present invention after subcutaneous administration of the formulations in rats (See Experiment 2), wherein vertical and horizontal axes show respectively the residual amount of calcitonin in the formulation (%) recovered from the animal and the time-course (days) after administration, and the symbols ▪ and  represent the formulations obtained in Example 5 and Reference Example 2, respectively. Fig. 4 shows the time-course of the accumulated amount of GRF (1-29) released from the formulations of the invention during Experiment 3, wherein vertical and horizontal axes show respectively the amount of GRF (1-29) released from the formulation and the time-course (days), said amount of GRF being indicated by percentage (%) of the initial amount. The symbols ▪ and  respectively show the formulations obtained in Examples 12 and 13. The following detailed examples are presented by way of illustration of specific embodiments of the invention. Reference Example 1 An aqueous solution containing 2 w/v% atelocollagen (21.25 ml) and an aqueous solution containing 10 mg/ml of growth hormone releasing factor (1-29) (GRF (1-29)) (7.5 ml) are uniformly admixed with care to prevent or minimize foam-generation, and the mixture is lyophilized. After the lyophilized material is added with distilled water to allow to swell, the mixture is thoroughly blended in a mortar to obtain a uniform liquid mixture. The mixture is charged in a syringe and linearly extruded from the syringe through a nozzle. The extruded material is dried and cut in an appropriate size to obtain an acidic compound-free column-shaped formulation containing 15 % by weight of GRF. Reference Example 2 An aqueous solution containing 2 w/v% atelocollagen (16.6 ml) and an aqueous solution containing 10 mg/ml of human calcitonin (6.8 ml) are mixed well with care to prevent or minimize foam-generation. The resultant mixture is lyophilized, added with an appropriate amount of distilled water to allow to swell, and blended thoroughly in a mortar to obtain a uniform liquid mixture. The mixture is molded in a similar manner as in Reference Example 1 to obtain a column-shaped formulation containing 17 % by weight of calcitonin, and no acidic compound. Example 1 Citric acid (25 mg) is added to an aqueous solution containing 2 w/v% atelocollagen (20 ml). The resultant solution and an aqueous solution containing 10 mg/ml of GRF (1-29) (7.5 ml) are thoroughly admixed with care to prevent or minimize foam-generation. The mixture is lyophilized, added with an appropriate amount of distilled water to allow to swell, blended well in a mortar to obtain a uniform liquid mixture. The mixture is charged in a syringe, linearly extruded therefrom through a nozzle, dried, and cut in an appropriate size. This gives a column-shaped formulation which contains 15 % by weight of GRF and 5 % by weight of citric acid. Example 2 Citric acid (50 mg) is added to an aqueous solution containing 2 w/v% atelocollagen (18.75 ml). The resultant solution and an aqueous solution containing 10 mg/ml of GRF (1-29) (7.5 ml) are thoroughly admixed with care to prevent or minimize foam-generation. The mixture is lyophilized, added with an appropriate amount of distilled water to allow to swell, blended well in a mortar to obtain a uniform liquid mixture. The mixture is molded in the same manner as in Example 1 to give a column-shaped formulation which contains 15 % by weight of GRF and 10 % by weight of citric acid. Example 3 Citric acid (25 mg) is added to an aqueous solution containing 2 w/v% atelocollagen (23.75 ml). The resultant solution and an aqueous solution containing 20 MU/ml of α-interferon (2 ml) are thoroughly admixed with care to prevent or minimize foam-generation. The mixture is lyophilized, added with an appropriate amount of distilled water to allow to swell, blended well in a mortar to obtain a uniform liquid mixture. The mixture is molded in the same manner as in Example 1 and subsequently molded into a needle-like shaped product to give a needle-like formulation containing α-interferon and 5 % by weight of citric acid. Example 4 Citric acid (100 mg) is added to an aqueous solution containing 2 w/v% atelocollagen (20 ml). The resultant solution and an aqueous solution containing 20 MU/ml of α-interferon (2 ml) are thoroughly admixed with care to prevent or minimize foam-generation. The mixture is lyophilized, added with an appropriate amount of distilled water to allow to swell, blended well in a mortar to obtain a uniform liquid mixture. The mixture is molded in the same manner as in Example 1 to give a bar-like formulation containing α-interferon and 20 % by weight of citric acid. Example 5 Citric acid (40 mg) is added to an aqueous solution containing 2 w/v% atelocollagen (14.6 ml). The resultant solution and an aqueous solution containing 10 mg/ml of human calcitonin (6.8 ml) are thoroughly admixed with care to prevent or minimize foam-generation. The mixture is lyophilized, added with an appropriate amount of distilled water to allow to swell, blended well in a mortar to obtain a uniform liquid mixture. The mixture is molded in the same manner as in Example 1 to give a column-shaped formulation containing 17 % by weight of calcitonin and 10 % by weight of citric acid. Example 6 Aspartic acid (40 mg) is added to an aqueous solution containing 2 w/v% atelocollagen (15 ml). The resultant solution and an aqueous solution containing 10 mg/ml of GRF (1-29) (6 ml) are thoroughly admixed with care to prevent or minimize foam-generation. The mixture is lyophilized, added with an appropriate amount of distilled water to allow to swell, blended well in a mortar to obtain a uniform liquid mixture. The mixture is molded in the same manner as in Example 1 to give a column-shaped formulation containing 15 % by weight of GRF and 10 % by weight of aspartic acid. Example 7 Aspartic acid (80 mg) is added to an aqueous solution containing 2 w/v% atelocollagen (13 ml). The resultant solution and an aqueous solution containing 10 mg/ml of GRF (1-29) (6 ml) are thoroughly admixed with care to prevent or minimize foam-generation. The mixture is lyophilized, added with an appropriate amount of distilled water to allow to swell, blended and kneaded well in a mortar to obtain a uniform liquid mixture. The mixture is molded in the same manner as in Example 1 to give a cylindrical-shaped formulation containing 15 % by weight of GRF and 20 % by weight of aspartic acid. Example 8 Aspartic acid (160 mg) is added to an aqueous solution containing 2 w/v% atelocollagen (9 ml). The resultant solution and an aqueous solution containing 10 mg/ml of GRF (1-29) (6 ml) are thoroughly admixed with care to prevent or minimize foam-generation. The mixture is lyophilized, added with an appropriate amount of distilled water to allow to swell, blended well in a mortar to obtain a uniform liquid mixture. The mixture is molded in the same manner as in Example 1 to give a rod-like formulation containing 15 % by weight of GRF and 40 % by weight of aspartic acid. Example 9 Glutamic acid (20 mg) is added to an aqueous solution containing 2 w/v% atelocollagen (16 ml). The resultant solution and an aqueous solution containing 10 mg/ml of GRF (1-29) (6 ml) are thoroughly admixed with care to prevent or minimize foam-generation. The mixture is lyophilized, added with an appropriate amount of distilled water to allow to swell, blended well in a mortar to obtain a uniform liquid mixture. The mixture is molded in the same manner as in Example 1 and subsequently subjected to a compression-molding to give a disk-like shaped formulation containing 15 % by weight of GRF and 5 % by weight of glutamic acid. Example 10 Glutamic acid (40 mg) is added to an aqueous solution containing 2 w/v% atelocollagen (15 ml). The resultant solution and an aqueous solution containing 10 mg/ml of GRF (1-29) (6 ml) are thoroughly admixed with care to prevent or minimize foam-generation. The mixture is lyophilized, added with an appropriate amount of distilled water to allow to swell, blended well in a mortar to obtain a uniform liquid mixture. The mixture is molded in the same manner as in Example 1 to give a column-shaped formulation containing 15 % by weight of GRF and 10 % by weight of glutamic acid. Example 11 Glutamic acid (80 mg) is added to an aqueous solution containing 2 w/v% atelocollagen (13 ml). The resultant solution and an aqueous solution containing 10 mg/ml of GRF (1-29) (6 ml) are thoroughly admixed with care to prevent or minimize foam-generation. The mixture is lyophilized, added with an appropriate amount of distilled water to allow to swell, blended well in a mortar to obtain a uniform liquid mixture. The mixture is molded in the same manner as in Example 1 to give a column-shaped formulation containing 15 % by weight of GRF and 20 % by weight of glutamic acid. Example 12 An aqueous solution containing 10 mg/ml of glycine (7 ml) is added to an aqueous solution containing 2 w/v% atelocollagen (26.25 ml). The resultant mixture and an aqueous solution containing 10 mg/ml of GRF (1-29) (10.5 ml) are thoroughly admixed with care to prevent or minimize foam-generation. The mixture is lyophilized, added with an appropriate amount of distilled water to allow to swell, blended well in a mortar to obtain a uniform liquid mixture. The mixture is charged in a syringe, linearly extruded therefrom through a nozzle, dried, and cut in appropriate size. This gives a column-shaped formulation containing 15 % by weight of GRF and 10 % by weight of glycine. Example 13 An aqueous solution containing 10 mg/ml of glycine (21 ml) is added to an aqueous solution containing 2 w/v% atelocollagen (19.25 ml). The resultant mixture and an aqueous solution containing 10 mg/ml of GRF (1-29) (10.5 ml) are thoroughly admixed with care to prevent or minimize foam-generation. The mixture is lyophilized, added with an appropriate amount of distilled water to allow to swell, blended well in a mortar to obtain a uniform liquid mixture. The mixture is charged in a syringe, linearly extruded therefrom through a nozzle, dried, and cut in appropriate size. This gives a column-shaped formulation containing 15 % by weight of GRF and 30 % by weight of glycine. Example 14 An aqueous solution containing 10 mg/ml of citric acid (2.5 ml) is added to an aqueous solution containing 2 w/v% atelocollagen (20 ml). The resultant mixture and an aqueous solution containing 10 mg/ml of GRF (1-29) (7.5 ml) are thoroughly admixed with care to prevent or minimize foam-generation. The mixture is lyophilized, added with an appropriate amount of distilled water to allow to swell, blended well in a mortar to obtain a uniform liquid mixture. The mixture is charged in a template and compressed to form a film, which is then dried and cut in an appropriate size to give a film-shaped formulation containing 15 % by weight of GRF and 5 % by weight of citric acid. Experiment 1 The column-shaped formulations obtained in Examples 1 and 2 and Reference Example 1, all of which contain GRF (1-29), were cut to obtain test samples of 10 mm length and subjected to a release test. Each of the samples was separately placed in 4 ml of a PBS(-) buffer solution, pH 7.4, and allowed to stand at 37 °C. The amount of GRF (1-29) released into the solution from the formulation was measured by high performance liquid chromatography every day over three days, and the accumulated amount of GRF (1-29) released from the formulation was determined. The correlation among the accumulated amount of GRF released from the formulation, releasing time and the amount of acidic compound incorporated is shown in Figs. 1 and 2 of the accompanying drawings. Experiment 2 The column-shaped formulation obtained according to the method disclosed in Example 5 was subcutaneously administered to rat. The formulation obtained in Reference Example 2 was administered in the same manner as in the above and made a control. After administration, the residual calcitonin content in the formulation recovered from the animal was measured at intervals of one to four days for 14 days. The dosage was adjusted so that one rat receives 1.7 mg of calcitonin. The calcitonin content was measured by removing the formulation from the rats, immediately dissolving the recovered formulation into water, and subjecting the aqueous solution to high performance liquid chromatography. The test results are shown in Fig. 3. Experiment 3 GRF (1-29)-containing formulations obtained in Examples 12 and 13 were cut to obtain test samples of 10 mm length. Each of the samples was placed in 4 ml of PBS (-) buffer, pH 7.4, and allowed to stand at 37 °C. The amount of GRF (1-29) released from each of the formulations was measured by means of high performance liquid chromatography, while totally replacing the buffer solution with fresh buffer solution after every sampling. The accumulated amount of GRF (1-29) released from each of the formulations is shown in Fig. 4. The above in vitro tests described in Experiments 1 and 3 reveal that the release rate or release profile of an active ingredient contained in the formulations of the present invention is successfully controlled by the amount of an acidic compound incorporated into the formulation. Experiment 2, in vivo test in rats, also shows the usefulness of the addition of an acidic compound for the purpose of controlling the release rate of an active ingredient. It was also observed in Experiment 2 that the degradation of collagen was accelerated by the addition of an acidic compound. The above Experiments, as a whole, exhibit an excellent advantage possessed by the formulation of the invention in that the formulation will be able to meet every requirement concerned with a controlled release of an active ingredient, particularly in clinical use.

Claims: Claims for the following Contracting States : AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE A sustained release formulation which is suitable for human and veterinary use, comprising bioactive proteins and peptides as an active ingredient and collagen as a carrier, characterized in that it comprises at least one pharmaceutically or veterinarily acceptable organic acidic compound, an aqueous solution of which has a pH below 7, or an acid anhydride or ester capable of generating one of the above-mentioned organic acidic compounds through hydrolysis. The formulation of Claim 1, wherein the collagen is atelocollagen. The formulation of Claim 1, wherein the bioactive proteins and peptides are selected from cytokines, hormones, hormone-releasing factors, hormone release-inhibiting factors, growth factors and enzymes. The formulation of Claim 3, wherein the cytokines are selected from interleukins, interferons, and colony-stimulating factors. The formulation of Claim 3, wherein the hormones are growth hormone and calcitonin. The formulation of Claim 3, wherein the hormone-releasing factors are growth hormone-releasing factors and luteinizing hormone-releasing hormone. The formulation of Claim 3, wherein the hormone release-inhibiting factor is somatostatine. The formulation of Claim 3, wherein the growth actors are selected from somatomedin, nerve growth factor, epidermal growth factor, transforming growth factor, fibroblast growth factor, erythropoietin (EPO) and platelet-derived growth factor. The formulation of Claim 3, wherein the enzymes are tissue plasminogen activator and urokinase. The formulation of Claim 1, wherein the organic acidic compound is a compound bearing carboxylic group or groups. The formulation of Claim 1, wherein the organic acidic compound is selected from aspartic acid, glutamic acid, glycine, alanine, citric acid, ascorbic acid, tartaric acid, succinic acid and acetic acid. The formulation of Claim 1, wherein the active ingredient is growth hormone-releasing factor and the organic acidic compound is selected from citric acid and glycine. The formulation of Claim 1, wherein the active ingredient is an interferon and the organic acidic compound is selected from citric acid and glycine. The formulation of Claim 1, wherein the active ingredient is calcitonin and the organic acidic compound is citric acid. A process for producing a sustained release formulation according to Claim 1, which process comprises a step to incorporate into a mixture of other starting materials for the formulation a compound or compounds selected from pharmaceutically or veterinarily acceptable organic acidic compounds and acid anhydrides or esters capable of generating one of the organic acidic compounds through hydrolysis. Claims for the following Contracting States : ES, GR A process for producing a sustained release formulation which is suitable for human and veterinary use, comprising bioactive proteins and peptides as an active ingredient and collagen as a carrier, which comprises at least one pharmaceutically or veterinarily acceptable organic acidic compound, an aqueous solution of which has a pH below 7, or an acid anhydride or ester capable of generating one of the above-mentioned organic acidic compounds through hydrolysis, which process comprises a step to incorporate into a mixture of other starting materials for the formulation a compound or compounds selected from organic acidic compounds and acid anhydrides or esters capable of generating one of the organic acidic compounds through hydrolysis. The process of Claim 1, wherein the collagen is atelocollagen. The process of Claim 1, wherein the bioactive proteins and peptides are selected from cytokines, hormones, hormone-releasing factors, hormone release-inhibiting factors, growth factors and enzymes. The process of Claim 3, wherein the cytokines are selected from interleukins, interferons, and colony-stimulating factors. The process of Claim 3, wherein the hormones are growth hormone and calcitonin. The process of Claim 3, wherein the hormone-releasing factors are growth hormone-releasing factors and luteinizing hormone-releasing hormone. The process of Claim 3, wherein the hormone release-inhibiting factor is somatostatine. The process of Claim 3, wherein the growth factors are selected from somatomedin, nerve growth factor, epidermal growth factor, transforming growth factor, fibroblast growth factor, erythropoietin (EPO) and platelet-derived growth factor. The process of Claim 3, wherein the enzymes are tissue plasminogen activator and urokinase. The formulation of Claim 1, wherein the organic acidic compound is a compound bearing carboxylic group or groups. The process of Claim 1, wherein the organic acidic compound is selected from aspartic acid, glutamic acid, glycine, alanine, citric acid, ascorbic acid, tartaric acid, succinic acid and acetic acid. The process of Claim 1, wherein the active ingredient is growth hormone-releasing factor and the organic acidic compound is selected from citric acid and glycine. The process of Claim 1, wherein the active ingredient is an interferon and the organic acidic compound is selected from citric acid and glycine. The process of Claim 1, wherein the active ingredient is calcitonin and the organic acidic compound is citric acid.

Inventors: FUJIOKA, KEIJI SUMITOMO PHARMACEUTICALS CO., LTD., MAEDA, MIHO C/O SUMITOMO PHARMACEUTICALS CO.LTD, SASAKI, YOSHIO C/O SUMITOMO PHARMACEUTICALS CO.LTD, SATO, SHIGEJI SUMITOMO PHARMACEUTICALS CO., LTD., TAKADA, YOSHIHIRO SUMITOMO PHARMACEUTICALS CO.,LTD, TAMURA, NOBUHIKO SUMITOMO PHARMACEUTICALS CO., LTD
Applicants: KOKEN CO. LTD., SUMITOMO PHARMACEUTICALS COMPANY, LIMITED
Application year: 1989
Main classification: A61K47
IPC codes: A61K9, A61K47